A handful of clinical studies have found deletions of the MTAP gene without concordant loss of CDKN2A or CDKN2B, and its deletion rate is higher than that of CDKN2A in certain cancers.18,23 In this study, we verified an indispensable role of MTAP loss in RCC progression. This evidence concerns the gene CDKN2B and cancer.